Xvivo Perfusion
396
SEK
+0,76 %
Mindre end 1K følgere
XVIVO
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Finansielt overblik og estimater
Ownership
+0,76%
-16,01%
-19,02%
-12,49%
-20,64%
+36,55%
+74,83%
+219,35%
+1.984,21%
Xvivo Perfusion operates in the medical technology industry and focuses on the development and manufacturing of systems for organ transplantation and perfusion. Examples of products that the company supplies include cannulas, organ storage and cooling solutions. The company's products are aimed at healthcare institutions and surgeons. Xvivo Perfusion operates globally, was founded in 1998 and is headquartered in Stockholm, Sweden.
Læs mereMarkedsværdi
12,47 mia. SEK
Aktieomsætning
9,96 mio. SEK
Omsætning
822,42 mio.
EBIT %
10,74 %
P/E
72,39
Udbytteafkast, %
-
Finanskalender
24.4
2025
Delårsrapport Q1'25
25.4
2025
Generalforsamling '25
11.7
2025
Delårsrapport Q2'25
ViserAlle indholdstyper

XVIVO, Audiocast with teleconference, Q4'24
Year-end report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q4 2024
Conference call on Year-end Report 2024
Enrollment completed five months early in the US clinical trial evaluating XVIVO’s heart preservation technology
XVIVO Perfusion appoints Lena Hagman as deputy CEO
Redeye: XVIVO Update - Excellent organic growth and a negative currency surprise

XVIVO, Audiocast with teleconference, Q3'24
Interim report January-September 2024
Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2024
Conference call on Interim Report
XVIVO to acquire a unique communication platform for the transplant process
Nomination Committee of XVIVO Perfusion AB (publ)
Results from European randomized controlled study using XVIVO’s heart technology published in The Lancet
Redeye: XVIVO Q2 Update - Another roaring quarter
